Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2020

A Research Analysis of Brolucizumab in the Real World

Michael S. Ip, MD

Show Description +

Michael S. Ip, MD, discusses the rate and risk stratification of the safety profile of brolucizumab-dbll (Beovu, Novartis) in the treatment of wet age-related macular degeneration (AMD), with reference to the HAWK and HARRIER phase 3 clinical trials. Dr. Ip talks about the retrospective analysis he and his colleagues conducted of real-world patients who received brolucizumab for the treatment of wet AMD and shares some interesting points from their analysis.

Posted: 11/05/2020

Keywords:

brolucizumab

•

Clinical Cases

•

HAWK and HARRIER

•

retina-meeting-recap

•

Wet AMD

•

Retina Subspecialty Day

Up Next

Comparing the Efficacy of Intravitreal Anti-VEGF Agents in the Treatment of Wet AMD

Comparing the Efficacy of Intravitreal Anti-VEGF Agents in the Treatment of Wet AMD

Diana V. Do, MD

$Managing Postoperative Refractive Errors$

Managing Postoperative Refractive Errors

Elizabeth Yeu, MD

IOL Power Calculations After Excimer Laser Surgery

IOL Power Calculations After Excimer Laser Surgery

Seth M. Pantanelli, MD

Entrustable Physician Activities

Entrustable Physician Activities

Thomas A. Oetting, MD

Ray-Tracing Optimization for Myopic LASIK

Ray-Tracing Optimization for Myopic LASIK

A. John Kanellopoulos, MD

A Deep-Learning Neural Network for Diagnosing Corneal Diseases

A Deep-Learning Neural Network for Diagnosing Corneal Diseases

Mohamed Abou Shousha, MD, FRCS, PhD

Predicting Graft Survival After PKP

Predicting Graft Survival After PKP

Eric J. Shiuey, MS

The Future of Limbal Stem Cell Transplantation

The Future of Limbal Stem Cell Transplantation

Ashiyana Nariani, MD, MPH,

Virtual Reality-Based Visual Field Testing

Virtual Reality-Based Visual Field Testing

Yvonne Ou, MD

Surgical Considerations in Neovascular Glaucoma: The Retina Perspective

Surgical Considerations in Neovascular Glaucoma: The Retina Perspective

Rishi P. Singh, MD

Evaluating Glaucomatous Progression in the Setting of Retinal Disease

Evaluating Glaucomatous Progression in the Setting of Retinal Disease

Yao Liu, MD, MS

Stimulating the Optic Nerve With Alternating Microcurrents

Stimulating the Optic Nerve With Alternating Microcurrents

Bernhard A. Sabel, PhD

Diagnostic and Therapeutic Vitrectomy in Uveitis

Diagnostic and Therapeutic Vitrectomy in Uveitis

Lisa J. Faia, MD

Receptor Interplay and Retinal Disease

Receptor Interplay and Retinal Disease

Peter Kaiser, MD

The Status of Cell Therapy for Atrophic AMD

The Status of Cell Therapy for Atrophic AMD

Allen C. Ho, MD

A Targeted Therapy for the Treatment of Choroidal Melanoma

A Targeted Therapy for the Treatment of Choroidal Melanoma

Carol Shields, MD

Deep Learning: OCT and Disease Prediction

Deep Learning: OCT and Disease Prediction

Tien Y. Wong, MD, MBBS, MPH, FRCS(Ed), Phd

Presbyopia-Correcting IOLs vs. Monofocal IOLs

Presbyopia-Correcting IOLs vs. Monofocal IOLs

Julie Schallhorn, MD

Genetic Targeting & Glaucoma

Genetic Targeting & Glaucoma

Milica Margeta, MD

Lessons Learned from the COVID-19 Pandemic

Lessons Learned from the COVID-19 Pandemic

Ranya Habash, MD

Light Adjustable Lens and Radial Keratotomy

Light Adjustable Lens and Radial Keratotomy

James D. Lehmann, MD

Does This New IOL Deliver?

Does This New IOL Deliver?

Devesh K. Varma, MD

Managing Cataract Surgery for Patients With High Hyperopia

Managing Cataract Surgery for Patients With High Hyperopia

Douglas Koch, MD

$How to Enhance Refractive Surgery of Hyperopia$

How to Enhance Refractive Surgery of Hyperopia

Jorge Alio MD

Maintaining Resilience and Avoiding Burnout

Maintaining Resilience and Avoiding Burnout

Julia Haller, MD

Evaluation of Avacincaptad Pegol for the Treatment of GA Associated With AMD

Evaluation of Avacincaptad Pegol for the Treatment of GA Associated With AMD

Donald J. D'Amico, MD

Management of High-Risk NPDR Today and Tomorrow

Management of High-Risk NPDR Today and Tomorrow

Charles C. Wykoff, MD, PhD

OCT-A Metrics Predict Diabetic Retinopathy Disease Progression

OCT-A Metrics Predict Diabetic Retinopathy Disease Progression

Nadia K. Waheed, MPH, MD

Back to All Videos

A Research Analysis of Brolucizumab in the Real World

Michael S. Ip, MD

Michael S. Ip, MD, discusses the rate and risk stratification of the safety profile of brolucizumab-dbll (Beovu, Novartis) in the treatment of wet age-related macular degeneration (AMD), with reference to the HAWK and HARRIER phase 3 clinical trials. Dr. Ip talks about the retrospective analysis he and his colleagues conducted of real-world patients who received brolucizumab for the treatment of wet AMD and shares some interesting points from their analysis.

Posted: 11/05/2020

Keywords:

brolucizumab

•

Clinical Cases

•

HAWK and HARRIER

•

retina-meeting-recap

•

Wet AMD

•

Retina Subspecialty Day

Please log in to leave a comment.

More From AAO: 2020 Coverage

Presbyopia-Correcting IOLs vs. Monofocal IOLs

Presbyopia-Correcting IOLs vs. Monofocal IOLs

Julie Schallhorn, MD

Genetic Targeting & Glaucoma

Genetic Targeting & Glaucoma

Milica Margeta, MD

Lessons Learned from the COVID-19 Pandemic

Lessons Learned from the COVID-19 Pandemic

Ranya Habash, MD

Light Adjustable Lens and Radial Keratotomy

Light Adjustable Lens and Radial Keratotomy

James D. Lehmann, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2020.